Want to see TSE:BETR full AI Analyst Report?
Top Page
BetterLife Pharma
(BETR)
Select Model
Select Model
Rating:40Underperform
Price Target:
C$0.26
▼(-30.54% Downside)
Action:Reiterated
Date:10/02/26
The score is primarily constrained by weak financial performance (no revenue, ongoing losses and cash burn, and negative equity indicating elevated financing risk). Technicals are also soft in the near term (below 20/50-day averages with slightly negative MACD), with only an oversold Stochastic offering modest support. Valuation is not supportive because the company is loss-making (negative P/E) and has no indicated dividend yield.
Positive Factors
Narrower Losses
Losses narrowing from 2022 indicates some spending discipline and could extend the runway relative to the prior period. However, the company remains unprofitable and has no reported revenue, so this improvement has not yet translated into self-funding or demonstrated commercial earnings.
Negative Factors
No Revenue and Persistent Losses
The absence of reported revenue alongside continuing net losses shows that the pipeline has not yet produced a commercial earnings base. Until meaningful commercialization or another revenue source emerges, ongoing investment needs will continue to pressure financial sustainability.
Read all positive and negative factors
Positive Factors
Negative Factors
Narrower Losses
Losses narrowing from 2022 indicates some spending discipline and could extend the runway relative to the prior period. However, the company remains unprofitable and has no reported revenue, so this improvement has not yet translated into self-funding or demonstrated commercial earnings.
Read all positive factors
BetterLife Pharma (BETR) vs. iShares MSCI Canada ETF (EWC)
Market Cap
C$163.77M
Dividend YieldN/A
Average Volume (3M)475.57K
Price to Earnings (P/E)―
Beta (1Y)0.51
Revenue GrowthN/A
EPS Growth-266.67%
CountryCA
Employees4
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.02
Shares Outstanding618,007,200
10 Day Avg. Volume277,510
30 Day Avg. Volume475,566
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)-0.75
Price to Sales (P/S)0.00
P/FCF Ratio-11.66
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.19
Revenue Forecast (FY)C$2.99B
BetterLife Pharma Business Overview & Revenue Model
Company Description
BetterLife Pharma Inc. is a biotechnology company focused on the global development and commercialization of therapeutic compounds, particularly for neurological disorders. The firm also innovates drug candidates utilizing complementary interferon...
BetterLife Pharma Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
18
Very Negative
Cash Flow
14
Very Negative
| Breakdown | TTM | Apr 2026 | Apr 2025 | Apr 2024 | Apr 2023 | Apr 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | -18.43K | -18.44K |
| EBITDA | -2.56M | -1.81M | 0.00 | -3.19M | -9.24M | -11.92M |
| Net Income | -3.48M | -1.50M | -3.52M | -2.89M | -9.02M | -12.16M |
Balance Sheet | ||||||
| Total Assets | 2.05M | 219.90K | 224.96K | 324.75K | 74.73K | 1.16M |
| Cash, Cash Equivalents and Short-Term Investments | 973.59K | 12.57K | 8.18K | 37.38K | 8.31K | 173.51K |
| Total Debt | 2.51M | 905.00K | 1.30M | 1.47M | 1.19M | 1.40M |
| Total Liabilities | 9.70M | 6.71M | 7.59M | 8.02M | 7.61M | 5.04M |
| Stockholders Equity | -10.94M | -9.78M | -10.68M | -10.81M | -10.73M | -3.88M |
Cash Flow | ||||||
| Free Cash Flow | -2.08M | -625.45K | -2.02M | -2.47M | -1.50M | -11.20M |
| Operating Cash Flow | -2.08M | -625.46K | -2.02M | -2.47M | -1.50M | -11.20M |
| Investing Cash Flow | 0.00 | 0.00 | 0.00 | 0.00 | 165.04K | -18.77K |
| Financing Cash Flow | 3.03M | 629.26K | 1.99M | 2.50M | 1.34M | 11.23M |
BetterLife Pharma Technical Analysis
Neutral
0.37
Price Trends
0.32
Negative
0.22
Positive
0.14
Positive
Market Momentum
-0.01
Positive
42.55
Neutral
9.26
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:BETR, the sentiment is Neutral. The current price of 0.37 is above the 20-day moving average (MA) of 0.32, above the 50-day MA of 0.32, and above the 200-day MA of 0.14, indicating a neutral trend. The MACD of -0.01 indicates Positive momentum. The RSI at 42.55 is Neutral, neither overbought nor oversold. The STOCH value of 9.26 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for TSE:BETR.
BetterLife Pharma Risk Analysis
BetterLife Pharma disclosed 20 risk factors in its most recent earnings report. BetterLife Pharma reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
BetterLife Pharma Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | C$26.76M | -15.10 | -72.15% | ― | 224.46% | 28.37% | |
50 Neutral | C$5.92M | -9.09 | -98.98% | ― | ― | 61.05% | |
46 Neutral | C$8.67M | -0.49 | -48.52% | ― | -13.00% | 75.31% | |
46 Neutral | C$6.93M | -3.93 | 39.05% | ― | ― | 25.70% | |
42 Neutral | C$961.39K | -0.81 | -85.01% | ― | 73.76% | -108.30% | |
40 Underperform | C$163.77M | -11.82 | 34.90% | ― | ― | -266.67% |
* Healthcare Sector Average
TSE:BETR
BetterLife Pharma
0.26
0.19
271.43%
TSE:CSCI
COSCIENS Biopharma
9.18
-1.59
-14.76%
TSE:PHRM
PharmaTher Holdings Ltd
0.06
-0.11
-64.71%
TSE:MRVL
Marvel Biosciences Corp
0.11
-0.13
-55.32%
TSE:MOOD
Doseology Sciences
0.12
-0.23
-65.71%
TSE:MDMA
PharmAla Biotech Holdings, Inc.
0.23
0.11
87.50%
BetterLife Pharma Corporate Events
Business Operations and StrategyDelistings and Listing ChangesShareholder Meetings
BetterLife Pharma Resets Shareholder Meeting to Advance Nasdaq Listing Plans
Positive
Sep 30, 2026
BetterLife Pharma has rescheduled its 2026 Annual General Meeting and reclassified it as an Annual General and Special Meeting to accommodate additional matters requiring shareholder approval. The virtual meeting will now be held on December 9, 20...
Business Operations and StrategyPrivate Placements and Financing
BetterLife Pharma Raises US$100 Million to Advance Neurological Drug BETR-001
Positive
Sep 17, 2026
BetterLife Pharma has closed a public offering of common shares and pre-funded warrants, raising approximately US$100 million to support the development of its BETR-001 program. The financing, led by Deep Track Capital alongside other specialist h...
Business Operations and StrategyExecutive/Board Changes
BetterLife Pharma Taps Veteran Biotech Strategist Charles Duncan to Lead Audit Committee
Positive
Aug 31, 2026
BetterLife Pharma has appointed Charles Duncan, PhD, a veteran biotechnology strategist and former top-ranked Wall Street biotech analyst, as Director and Chair of its Audit Committee. Duncan brings nearly three decades of experience spanning corp...
Business Operations and StrategyPrivate Placements and Financing
BetterLife Pharma Prices US$100 Million Equity Offering to Advance Neurology Trials
Positive
Aug 28, 2026
BetterLife Pharma has priced a public offering of up to 555 million common shares and pre-funded warrants at C$0.25 per share, targeting gross proceeds of US$100 million. The securities will be sold on a commercially reasonable efforts basis throu...
Business Operations and StrategyPrivate Placements and FinancingRegulatory Filings and Compliance
BetterLife Pharma Plans Equity Offering to Advance Neurological Trial Program
Positive
Aug 25, 2026
BetterLife Pharma Inc., a Vancouver-based biotechnology company, is focused on developing BETR-001, a non-hallucinogenic LSD derivative for neurological disorders, supported by patents covering synthesis and pending protection for composition and ...
Business Operations and StrategyExecutive/Board Changes
BetterLife Pharma Names Veteran Migraine Specialist as CMO to Drive BETR-001 Development
Positive
Aug 19, 2026
BetterLife Pharma has appointed neurologist and headache specialist Dr. Mahan Chehrenama as Chief Medical Officer to lead clinical development of its lead asset, BETR-001, a non-hallucinogenic neuroplastogen being advanced toward an IND applicatio...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.